FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2952300316> ?p ?o ?g. }

• W2952300316 endingPage "82" @default.
• W2952300316 startingPage "78" @default.
• W2952300316 abstract "There have been a number of angiogenic gene therapy trials, yielding mixed results as to efficacy, but demonstrating uniform short-term treatment safety. Data regarding long-term safety of angiogenic gene therapy are limited. Double-blind VIF-CAD trial (NCT00620217) assessed myocardial perfusion and clinical data in 52 refractory coronary artery disease (CAD) patients randomized into treatment (VIF; n = 33) and Placebo (n = 19) arms. VIF group received electromechanical system NOGA-guided intramyocardial injections of VEGF-A165/bFGF plasmid (VIF) into ischemic regions, while the Placebo group-placebo plasmid injections. Full 1-year follow-up data have been published. This study presents the results of over 10-year (median 133 months, range 95-149) safety follow-up of VIF-CAD patients. Overall, 12 (36.4%) patients died in VIF and 8 (42.1%) in Placebo group (P = .68). Cardiovascular mortality was 12/33 (36.4%) in the VIF group and 6/19 (31.6%) in Placebo group (P = .73). Two Placebo patients died due to malignancies, but no VIF patients (P = .17). The Kaplan-Meier curves of combined endpoint: cardiovascular mortality, myocardial infarction and stroke were similar for both patient groups (P = .71). Odds ratio of Placebo group increasing (reaching a worse) their CCS class versus VIF was non-significant (OR 1.28, 95% CI = 0.66-2.45; P = .47). However, CCS class improved in time irrespectively of treatment-OR of reaching a less favorable CCS class per each year of follow-up was 0.74 (95% CI 0.685-0.792; P < .0001, pooled data). There were no differences in readmission rates. Intramyocardial VEGF-A165/bFGF plasmid administration appears safe, with no evidence of an increase in the incidence of death, malignancy, myocardial infarction or stroke during 10-year follow-up in this limited patient population." @default.
• W2952300316 created "2019-06-27" @default.
• W2952300316 creator A5002939631 @default.
• W2952300316 creator A5008641481 @default.
• W2952300316 creator A5021855229 @default.
• W2952300316 creator A5033136642 @default.
• W2952300316 creator A5059085598 @default.
• W2952300316 creator A5063611857 @default.
• W2952300316 creator A5076993879 @default.
• W2952300316 creator A5087525266 @default.
• W2952300316 creator A5088649343 @default.
• W2952300316 date "2019-09-01" @default.
• W2952300316 modified "2023-10-18" @default.
• W2952300316 title "Long-term follow-up and safety assessment of angiogenic gene therapy trial VIF-CAD: Transcatheter intramyocardial administration of a bicistronic plasmid expressing VEGF-A165/bFGF cDNA for the treatment of refractory coronary artery disease" @default.
• W2952300316 cites W1541887683 @default.
• W2952300316 cites W1972221671 @default.
• W2952300316 cites W2013932714 @default.
• W2952300316 cites W2018236556 @default.
• W2952300316 cites W2039337359 @default.
• W2952300316 cites W2049427543 @default.
• W2952300316 cites W2073645982 @default.
• W2952300316 cites W2085357369 @default.
• W2952300316 cites W2097401006 @default.
• W2952300316 cites W2115260446 @default.
• W2952300316 cites W2125150769 @default.
• W2952300316 cites W2152843042 @default.
• W2952300316 cites W2159376400 @default.
• W2952300316 cites W2162844134 @default.
• W2952300316 cites W2741933191 @default.
• W2952300316 cites W2883681062 @default.
• W2952300316 cites W2886898998 @default.
• W2952300316 doi "https://doi.org/10.1016/j.ahj.2019.06.009" @default.
• W2952300316 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31288177" @default.
• W2952300316 hasPublicationYear "2019" @default.
• W2952300316 type Work @default.
• W2952300316 sameAs 2952300316 @default.
• W2952300316 citedByCount "13" @default.
• W2952300316 countsByYear W29523003162020 @default.
• W2952300316 countsByYear W29523003162021 @default.
• W2952300316 countsByYear W29523003162022 @default.
• W2952300316 countsByYear W29523003162023 @default.
• W2952300316 crossrefType "journal-article" @default.
• W2952300316 hasAuthorship W2952300316A5002939631 @default.
• W2952300316 hasAuthorship W2952300316A5008641481 @default.
• W2952300316 hasAuthorship W2952300316A5021855229 @default.
• W2952300316 hasAuthorship W2952300316A5033136642 @default.
• W2952300316 hasAuthorship W2952300316A5059085598 @default.
• W2952300316 hasAuthorship W2952300316A5063611857 @default.
• W2952300316 hasAuthorship W2952300316A5076993879 @default.
• W2952300316 hasAuthorship W2952300316A5087525266 @default.
• W2952300316 hasAuthorship W2952300316A5088649343 @default.
• W2952300316 hasConcept C104317684 @default.
• W2952300316 hasConcept C111599444 @default.
• W2952300316 hasConcept C121332964 @default.
• W2952300316 hasConcept C126322002 @default.
• W2952300316 hasConcept C127413603 @default.
• W2952300316 hasConcept C141071460 @default.
• W2952300316 hasConcept C142424586 @default.
• W2952300316 hasConcept C142724271 @default.
• W2952300316 hasConcept C156957248 @default.
• W2952300316 hasConcept C164705383 @default.
• W2952300316 hasConcept C168563851 @default.
• W2952300316 hasConcept C185592680 @default.
• W2952300316 hasConcept C203092338 @default.
• W2952300316 hasConcept C204787440 @default.
• W2952300316 hasConcept C27081682 @default.
• W2952300316 hasConcept C2778213512 @default.
• W2952300316 hasConcept C2780645631 @default.
• W2952300316 hasConcept C500558357 @default.
• W2952300316 hasConcept C535046627 @default.
• W2952300316 hasConcept C55493867 @default.
• W2952300316 hasConcept C71924100 @default.
• W2952300316 hasConcept C78519656 @default.
• W2952300316 hasConcept C87355193 @default.
• W2952300316 hasConcept C90924648 @default.
• W2952300316 hasConceptScore W2952300316C104317684 @default.
• W2952300316 hasConceptScore W2952300316C111599444 @default.
• W2952300316 hasConceptScore W2952300316C121332964 @default.
• W2952300316 hasConceptScore W2952300316C126322002 @default.
• W2952300316 hasConceptScore W2952300316C127413603 @default.
• W2952300316 hasConceptScore W2952300316C141071460 @default.
• W2952300316 hasConceptScore W2952300316C142424586 @default.
• W2952300316 hasConceptScore W2952300316C142724271 @default.
• W2952300316 hasConceptScore W2952300316C156957248 @default.
• W2952300316 hasConceptScore W2952300316C164705383 @default.
• W2952300316 hasConceptScore W2952300316C168563851 @default.
• W2952300316 hasConceptScore W2952300316C185592680 @default.
• W2952300316 hasConceptScore W2952300316C203092338 @default.
• W2952300316 hasConceptScore W2952300316C204787440 @default.
• W2952300316 hasConceptScore W2952300316C27081682 @default.
• W2952300316 hasConceptScore W2952300316C2778213512 @default.
• W2952300316 hasConceptScore W2952300316C2780645631 @default.
• W2952300316 hasConceptScore W2952300316C500558357 @default.
• W2952300316 hasConceptScore W2952300316C535046627 @default.
• W2952300316 hasConceptScore W2952300316C55493867 @default.
• W2952300316 hasConceptScore W2952300316C71924100 @default.
• W2952300316 hasConceptScore W2952300316C78519656 @default.
• W2952300316 hasConceptScore W2952300316C87355193 @default.

• next